The stock's fall snapped a two-day winning streak.

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...